Back to Search
Start Over
[A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy].
- Source :
-
Rinsho shinkeigaku = Clinical neurology [Rinsho Shinkeigaku] 2023 Mar 29; Vol. 63 (3), pp. 152-158. Date of Electronic Publication: 2023 Mar 25. - Publication Year :
- 2023
-
Abstract
- The patient was a 44-year-old man who developed cognitive impairment beginning at the age of 35 years that gradually worsened. The cognitive impairment led to a difficult social life, and he retired from his company. After hospitalization and workup, he was diagnosed with primary progressive multiple sclerosis (PPMS) that presented only with cognitive impairment for 10 years. Since he had multiple predictive factors for poor prognosis, anti-CD20 monoclonal antibody therapy was implemented. Cognitive impairment and cerebral blood flow SPECT findings improved, and he returned to a social life 3 months later. Anti-CD20 monoclonal antibody therapy was effective in improving cognitive impairment in a case of an advanced stage of PPMS.
- Subjects :
- Male
Humans
Adult
Antibodies, Monoclonal
Multiple Sclerosis drug therapy
Multiple Sclerosis, Chronic Progressive complications
Multiple Sclerosis, Chronic Progressive drug therapy
Multiple Sclerosis, Chronic Progressive psychology
Cognitive Dysfunction drug therapy
Cognitive Dysfunction etiology
Antineoplastic Agents therapeutic use
Subjects
Details
- Language :
- Japanese
- ISSN :
- 1882-0654
- Volume :
- 63
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Rinsho shinkeigaku = Clinical neurology
- Publication Type :
- Academic Journal
- Accession number :
- 36843088
- Full Text :
- https://doi.org/10.5692/clinicalneurol.cn-001779